Management is key to a successful business... IMHO
Biography of Daniel Kenny
From Bloomberg Business
* Mr. Daniel Kenny has been the Chief Executive Officer of Oncosil Medical Limited since January 5, 2015 and serves as its Managing Director.
* Mr. Kenny served as Chief Commercial Officer and Vice President of Business Development at ABIVAX S.A. since October 2014.
* He is an accomplished biopharmaceutical business leader, with almost 30 years' experience in the Global Pharmaceutical industry.
* In his career he has developed and successfully driven business with industry leaders such as Roche (strategic marketing plans for the launch of Tamiflu(R) ) and Allergan. Prior to joining ABIVAX,
* he served as Global Franchise Head at Baxter Vaccines. In this role, he led a successful reinvigoration of the base commercial business, significantly exceeding the financial plan for the Franchise in each of the three years of his tenure.
* Before assuming this post, he served as Vice President Baxter BioScience, EMEA with responsibility for all marketing and key business programmes in support of regional sales exceeding $1.9billion.
* He completed over 10 years in clinical research in the fields of ophthalmology and HIV/AIDS prior to join the pharmaceutical industry.
* He has been a Director of Oncosil Medical Limited since November 28, 2014.
* Mr. Kenny is a graduate in Physics from the University of New South Wales and has completed Executive business studies at both INSEAD and the London Business School.
http://www.bloomberg.com/research/stocks/private/person.asp?personId=275657660&privcapId=23077988
- Forums
- ASX - By Stock
- OSL
- Biography of Daniel Kenny - Management is key to a successful business... IMHO
OSL
oncosil medical ltd
Add to My Watchlist
5.69%
!
$1.16

Biography of Daniel Kenny - Management is key to a successful business... IMHO
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M |
Open | High | Low | Value | Volume |
$1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 412 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | 1.160 |
1 | 7500 | 1.080 |
2 | 19761 | 1.050 |
1 | 2500 | 1.030 |
1 | 550 | 1.020 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 412 | 1 |
1.200 | 8677 | 1 |
1.245 | 2418 | 1 |
1.250 | 46027 | 1 |
1.300 | 1500 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online